发明公开
- 专利标题: BLOOD CELL-FREE DNA-BASED METHOD FOR PREDICTING PROGNOSIS OF BREAST CANCER TREATMENT
-
申请号: EP22904598.4申请日: 2022-12-05
-
公开(公告)号: EP4447069A1公开(公告)日: 2024-10-16
- 发明人: CHO, Eun-Hae , AHN, Jin Mo , LEE, Junnam , LEE, Tae-Rim , SOHN, Joohyuk , KIM, Gun Min , KIM, Min Hwan
- 申请人: GC Genome Corporation
- 申请人地址: KR Yongin-si, Gyeonggi-do 16924 107, Ihyeon-ro 30beon-gil, Giheung-gu
- 代理机构: Mewburn Ellis LLP
- 优先权: KR20210172562 20211206
- 国际公布: WO2023106768 20230615
- 主分类号: G16H50/50
- IPC分类号: G16H50/50 ; G16H20/40 ; G16H50/20 ; G16B30/10 ; G16B50/00 ; G16H30/40 ; C12Q1/6886 ; G01N33/483 ; G06T7/00 ; G06F17/18
摘要:
The present invention relates to a blood cell-free DNA-based method for predicting prognosis of breast cancer treatment and, more particularly, to a cell-free DNA-based method for predicting prognosis of breast cancer treatment, the method comprising a step of extracting cell-free DNA (cfDNA) from a biological sample before anticancer treatment, acquiring sequence information, then obtaining an I-score by using normalization correction and regression analysis of chromosomal regions, and analyzing the I-score and image information of the breast together after the anticancer treatment. A method for predicting prognosis of breast cancer, according to the present invention, uses next generation sequencing (NGS) so as to increase the accuracy of predicting the prognosis of a breast cancer patient and also increase the accuracy of prognosis prediction based on a very low concentration cell-free DNA of which detection has been difficult, thereby increasing the commercial utilization thereof. Therefore, the method of the present invention is useful in determining the prognosis of a breast cancer patient.
信息查询